Drugmakers Lose Bid For 'Indefinite' Extension In FTC Case

Law360, New York (December 12, 2013, 5:44 PM EST) -- The Federal Trade Commission's pay-for-delay case against Actavis Inc. and other drugmakers is now set to resume nearly six months after the U.S. Supreme Court revived the suit, with a Georgia judge on Tuesday giving the defendants 21 days to respond to the watchdog's complaint.

Though the Supreme Court ruled in June that reverse payment patent settlements could be challenged under antitrust law, the Actavis case that spawned the landmark decision had been stuck in procedural limbo for months at the Eleventh Circuit. More recently, it appeared that the case might get caught in a procedural dispute over related class action...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!